381 related articles for article (PubMed ID: 12208763)
1. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection.
Tsung K; Dolan JP; Tsung YL; Norton JA
Cancer Res; 2002 Sep; 62(17):5069-75. PubMed ID: 12208763
[TBL] [Abstract][Full Text] [Related]
2. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
3. Ca2+-dependent, Fas- and perforin-independent apoptotic death of allografted tumor cells by a type of activated macrophage.
Yoshida R; Sanchez-Bueno A; Yamamoto N; Einaga-Naito K
J Immunol; 1997 Jul; 159(1):15-21. PubMed ID: 9200433
[TBL] [Abstract][Full Text] [Related]
4. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12.
Tsung K; Meko JB; Tsung YL; Peplinski GR; Norton JA
J Immunol; 1998 Feb; 160(3):1369-77. PubMed ID: 9570556
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of in vitro interleukin 10 production after in vivo administration of interleukin 18 is activated macrophage-dependent and is probably not involved in the antitumor effects of interleukin 18.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Ikegami H; Kurimoto M
Anticancer Res; 1998; 18(6A):4267-74. PubMed ID: 9891477
[TBL] [Abstract][Full Text] [Related]
7. The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target.
Segal JG; Lee NC; Tsung YL; Norton JA; Tsung K
Cancer Res; 2002 Aug; 62(16):4696-703. PubMed ID: 12183428
[TBL] [Abstract][Full Text] [Related]
8. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
Evans R; Duffy T
J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.
Sinha P; Clements VK; Ostrand-Rosenberg S
Cancer Res; 2005 Dec; 65(24):11743-51. PubMed ID: 16357187
[TBL] [Abstract][Full Text] [Related]
10. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.
Lee SH; Bar-Haim E; Machlenkin A; Goldberger O; Volovitz I; Vadai E; Tzehoval E; Eisenbach L
Cancer Gene Ther; 2004 Mar; 11(3):237-48. PubMed ID: 14739939
[TBL] [Abstract][Full Text] [Related]
11. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
[TBL] [Abstract][Full Text] [Related]
13. Critical role of NK1+ T cells in IL-12-induced immune responses in vivo.
Kawamura T; Takeda K; Mendiratta SK; Kawamura H; Van Kaer L; Yagita H; Abo T; Okumura K
J Immunol; 1998 Jan; 160(1):16-9. PubMed ID: 9551949
[TBL] [Abstract][Full Text] [Related]
14. Perforin/Fas-ligand double deficiency is associated with macrophage expansion and severe pancreatitis.
Spielman J; Lee RK; Podack ER
J Immunol; 1998 Dec; 161(12):7063-70. PubMed ID: 9862744
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of host signal transducer and activator of transcription factor 6 results in cure with cyclophosphamide and interleukin 12 immunotherapy.
Norton JA; Li M; Lee NC; Tsung K
Ann Surg Oncol; 2006 Jan; 13(1):118-24. PubMed ID: 16372153
[TBL] [Abstract][Full Text] [Related]
16. Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis.
Terrazas LI; Montero D; Terrazas CA; Reyes JL; RodrÃguez-Sosa M
Int J Parasitol; 2005 Nov; 35(13):1349-58. PubMed ID: 16126211
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
18. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
[TBL] [Abstract][Full Text] [Related]
19. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide.
Mullins DW; Burger CJ; Elgert KD
J Immunol; 1999 Jun; 162(11):6811-8. PubMed ID: 10352302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]